A Phase 1 randomized trial of homologous and heterologous filovirus vaccines with a late booster dose
Rostad C, Yildirim I, Kao C, Yi J, Kamidani S, Peters E, Stephens K, Gibson T, Hsiao H, Singh K, Spearman P, McCracken C, Agbakoba V, Tomashek K, Goll J, Gelber C, Johnson R, Lee S, Maner-Smith K, Bosinger S, Ortlund E, Chen X, Anderson L, Wrammert J, Suthar M, Rouphael N, Anderson E. A Phase 1 randomized trial of homologous and heterologous filovirus vaccines with a late booster dose. Npj Vaccines 2024, 9: 255. PMID: 39715748, PMCID: PMC11666633, DOI: 10.1038/s41541-024-01042-4.Peer-Reviewed Original ResearchAntibody-dependent cellular cytotoxicityMVA-BNPrime-boostHeterologous prime-boost strategyPrime-boost schedulePhase 1 trialSevere viral hemorrhagic feverPrime-boost strategyHealthy U.S. adultsHomologous prime-boostViral hemorrhagic feverGlobal health priorityCellular responsesCellular cytotoxicityVaccine regimensImmunological memoryNeutralizing antibodiesFollow-upFilovirus vaccinesRe-exposureReactogenicityHemorrhagic feverVaccineMultiple filovirusesHealth priority
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply